Literature DB >> 12555159

Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction.

James E Udelson1, Marvin A Konstam.   

Abstract

BACKGROUND: A major advance in understanding the pathophysiology of the heart failure syndrome has been an understanding of the process of left ventricular (LV) remodeling. After any insult to the left ventricle resulting in diminished systolic performance and stroke volume, a series of histopathologic changes in the myocardium and structural changes in the LV chamber occurs over time. METHODS AND
RESULTS: Early work on understanding this process of LV remodeling emerged from the studies of Pfeffer and colleagues, who used a rat model of myocardial infarction (MI). Compared to those with smaller MIs, rats with larger induced MIs underwent a substantially greater degree of chamber remodeling over time, and importantly, these structural changes were associated with significantly higher morality. These studies established for the first time the relation between the structural changes now widely known as LV remodeling and a natural history outcome in the setting of LV systolic dysfunction. Subsequently, these investigators demonstrated that angiotensin-converting enzyme (ACE) inhibition with captopril, when initiated soon after the induced MI, attenuated the remodeling process. Also observed was an improvement in survival among rats in whom the remodeling process has been attenuated. These important data paved the way for human studies that have subsequently provided substantial evidence to support two important concepts: (1) that LV remodeling is related to clinical outcomes that represent the natural history of the heart failure syndrome such as mortality and surrogate markers of the progression of heart failure, and (2) that therapeutic interventions in humans that slow or reverse the process of LV remodeling, such as ACE inhibitors and beta-blockers, appear to have a favorable effect on that natural history.
CONCLUSIONS: This review will examine the issue of the relation between LV remodeling and clinical outcomes in the human heart failure syndrome from several interrelated aspects: (1) the relation between LV volume at one time point and subsequent oucome, (2) the relation between changes in LV volumes over time (LV remodeling) and clinical outcomes, and (3) the relation between the effect of medical therapeutic interventions on the LV remodeling process and the effect of those same medical interventions on natural history outcomes in human heart failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12555159     DOI: 10.1054/jcaf.2002.129289

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  22 in total

Review 1.  The historical and conceptual evolution of radionuclide assessment of myocardial viability.

Authors:  James E Udelson; Robert O Bonow; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2004 May-Jun       Impact factor: 5.952

2.  The use of H1-receptor antagonists and left ventricular remodeling in patients on chronic hemodialysis.

Authors:  Kiyotsugu Omae; Tetsuya Ogawa; Masao Yoshikawa; Kosaku Nitta
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

Review 3.  Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure.

Authors:  Shweta R Motiwala; Hanna K Gaggin
Journal:  Curr Heart Fail Rep       Date:  2016-10

4.  Smaller Left Ventricle Size at Noncontrast CT Is Associated with Lower Mortality in COPDGene Participants.

Authors:  George R Washko; Pietro Nardelli; Samuel Y Ash; Farbod N Rahaghi; Gonzalo Vegas Sanchez-Ferrero; Carolyn E Come; Mark T Dransfield; Ravi Kalhan; MeiLan K Han; Surya P Bhatt; J Michael Wells; Carrie L Pistenmaa; Alejandro A Diaz; James C Ross; Stephen Rennard; Gabriela Querejeta Roca; Amil M Shah; Kendra Young; Gregory L Kinney; John E Hokanson; Alvar Agustí; Raúl San José Estépar
Journal:  Radiology       Date:  2020-05-05       Impact factor: 11.105

5.  Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance.

Authors:  Joseph R Carver; Dava Szalda; Bonnie Ky
Journal:  Semin Oncol       Date:  2013-04       Impact factor: 4.929

Review 6.  Cardiac Magnetic Resonance Quantification of Structure-Function Relationships in Heart Failure.

Authors:  Kim-Lien Nguyen; Peng Hu; J Paul Finn
Journal:  Heart Fail Clin       Date:  2020-10-28       Impact factor: 3.179

7.  Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs).

Authors:  D Dirk Bonnema; Carson S Webb; Weems R Pennington; Robert E Stroud; Amy E Leonardi; Leslie L Clark; Catherine D McClure; Laura Finklea; Francis G Spinale; Michael R Zile
Journal:  J Card Fail       Date:  2007-09       Impact factor: 5.712

8.  Left Ventricular Dyssynchrony After Acute Myocardial Infarction is a Powerful Indicator of Left Ventricular Remodeling.

Authors:  Jum Suk Ko; Myung Ho Jeong; Min Goo Lee; Shin Eun Lee; Won Yu Kang; Soo Hyun Kim; Keun-Ho Park; Doo Sun Sim; Nam Sik Yoon; Hyun Ju Yoon; Young Joon Hong; Hyung Wook Park; Ju Han Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang
Journal:  Korean Circ J       Date:  2009-06-30       Impact factor: 3.243

Review 9.  Cell-based therapy for heart disease: a clinically oriented perspective.

Authors:  Philippe Menasche
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

10.  Ischemic patterns assessed by positron emission tomography predict adverse outcome in patients with idiopathic dilated cardiomyopathy.

Authors:  Richard M de Jong; Rene A Tio; Pim van der Harst; Adriaan A Voors; Paul M Koning; Clark J A M Zeebregts; Dirk J van Veldhuisen; Rudi A J O Dierckx; Riemer H J A Slart
Journal:  J Nucl Cardiol       Date:  2009-08-01       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.